CRFA Awards 16 New Grants and Fellowships

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

ALEXANDRIA, Va--The Cancer Research Foundation of America (CRFA), a national, nonprofit organization dedicated to cancer prevention through scientific research and education, has awarded 16 new grants and fellowships totaling $528,605 for cancer prevention research. The money went to 14 institutions, most of it for 10 laboratory-based studies.

ALEXANDRIA, Va--The Cancer Research Foundation of America (CRFA), a national, nonprofit organization dedicated to cancer prevention through scientific research and education, has awarded 16 new grants and fellowships totaling $528,605 for cancer prevention research. The money went to 14 institutions, most of it for 10 laboratory-based studies.

The lone clinical trial funded--a randomized phase II chemoprevention study at the University of Colorado Health Sciences Center--will test selenium vs placebo in patients with localized prostate cancer. Drs. Karen Kelly and Nadine Mikhaeel-Kamel are the recipients.

Articles in this issue
ACS Takes Aim at Proposed Federal Tobacco Bills
Loan Defaults Disqualify 1,402
FDA Gives OK to Seven New Cancer Drugs in 1997
HIA Chemo Promising in Colon Cancer Liver Mets
Proposed Budget Spells ‘Good News’ for NCI
Proposed Budget Has Extra Funds for FDA Teen Smoking Effort
CRFA Awards 16 New Grants and Fellowships
Cancer Pain Treatment Requires Clear Terminology About ‘Addiction’
‘Staging’ of the Managed Care Market Is Crucial
NCI, EPA Attempt to Resolve Differences Over Childhood Cancer
IGF-1 Identified as Possible Risk Factor For Prostate Cancer
Radiologic Staging Tests Unwarranted In Small Breast Cancer
Immediate Reconstruction Safe After Previous Irradiation
AIDS Mortality Drops Dramatically in New York City: 1997 Data
Experts Moving Toward Consensus on Providing Access to Clinical Trials
Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content
Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Tim Cortese
November 25th 2024
Article

A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma

Tim Cortese
November 22nd 2024
Article

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer

Tim Cortese
November 21st 2024
Article

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.